Navigation Links
Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
Date:1/15/2008

REINACH, Switzerland, January 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received authorisation from the U.S. Food and Drug Administration (FDA) to conduct a Phase II 'intravenous-to-oral' switch trial with iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with intravenous (IV) vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI will receive IV vancomycin for the first two days of treatment and will then be randomised to either continue to receive IV vancomycin or be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Iclaprim is also being developed as an intravenous formulation for two indications: cSSSI and nosocomial pneumonia. In the cSSSI indication the drug candidate has completed its pivotal Phase III trial programme and is currently in an NDA-filing process. In the nosocomial pneumonia indication, the drug candidate is currently in Phase II.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows good oral bioavailability and consequently offers the potential for intravenous-to- oral switch therapy. We believe that intravenous-to-oral switch therapy is important as it could provide a means to enhance patient comfort, reduce risk of spread of infection and reduce hospital-associated healthcare costs. In parallel with this Phase II trial, we are continuing our work on th
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida-Supported CME Symposium Available Online
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Arpida Presents Preclinical Data on AR-2474 at ICAAC
4. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
5. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
6. Arpida Interim Results for six Months to 30 June 2007
7. Genta Receives Notice of Non-Compliance With NASDAQ Rule
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
10. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
11. Aida Receives Chinese Government Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... are efficient but involve a range of resource ... seed) and pine resin and a clever recycling ... a highly interesting alternative. Their study will be ... . , ,We think our discovery can open ... the batteries of the future, says Daniel Brandell, ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 /PRNewswire/ ... firm, and The Channel Group ("TCG"), a leader ... transition advisors, have formed an alliance to expand ... to prospective clients. With the alliance, Burnham Securities ... in the scientific, clinical medicine and management in ...
(Date:9/29/2014)... September 29, 2014 ... competition to transform network connectivity as customers put ... ProLabs , the leading independent provider ... the findings of their survey conducted at the ... top optical communications professionals from across the globe. ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3End of an Era: OEM Dominance - Could it be a Thing of the Past? 2
... love this provider of really useful, reliable, and not to mention ... fact came to light a few weeks ago when the Internet ... gourmet chefs to prepare meals (free to employees) for its brainy ... will soon be leaving to start a chain of natural foods ...
... all the time. A company hires an independent computer programmer ... uses to run an important part of its business. All ... ,Even when there is a written contract, the specifics of ... not addressed. , ,Years later (perhaps as a result of ...
... Wis. -- Researchers at the USDA Forest Service ... agencies and the pulp and paper industry in an ... of the paper commonly used in business and government ... , ,The federal government annually buys some 500,000 tons ...
Cached Biology Technology:Is Google's cafeteria a competitive weapon? 2Is Google's cafeteria a competitive weapon? 3Is Google's cafeteria a competitive weapon? 4Who owns software developed for your company? 2Who owns software developed for your company? 3Who owns software developed for your company? 4Reducing brightness to make a better paper 2Reducing brightness to make a better paper 3
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 ... around the globe dropped 52 percent, says the ... Wildlife Fund (WWF). This biodiversity loss occurs disproportionately ... use of high-income countries. , In addition to ... data point to other warning signs about the ...
(Date:9/29/2014)... Parents with children at home should use ventilation when ... University are recommending, after a new study showed an ... symptoms and chronic bronchitis. , "In homes where a ... asthma and wheezing is higher than in homes where ... Smit, an associate professor in the College of Public ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and ... pine trees over tens of millions of acres in ... , But contrary to popular belief, these pests ... like those that have recently swept through the region. ... the ecological severity of fires than these bark-boring beetles. ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... fingers (metacarpals) and toes (metatarsals) and can be restricted ... disease is called brachydactyly type E (Greek for short ... the research group of Professor Friedrich C. Luft at ... cooperation between the Charit Medical Faculty and the Max ...
... Researchers have discovered why plants and animals had a hard ... 250 million years ago. The reason: global warming. ... survived the extinction didn,t fully recover for 5 million years. ... of how life was forever altered by giant volcanic eruptions ...
... meadows in the Pacific Northwest are declining rapidly due to ... seasons and other factors allow trees to invade these unique ... The process appears to have been going on for ... Park, a subalpine meadow complex in the central Oregon Cascade ...
Cached Biology News:New findings on gene regulation and bone development 2New findings on gene regulation and bone development 3New findings on gene regulation and bone development 4After long-ago mass extinction, global warming hindered species' recovery 2After long-ago mass extinction, global warming hindered species' recovery 3After long-ago mass extinction, global warming hindered species' recovery 4Mountain meadows dwindling in the Pacific Northwest 2
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
MagSi monodispers, magnetic silica particles with modified surface for SO3 coupling chemistry....
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
Biology Products: